Zhejiang CONBA Pharmaceutical Co Ltd

Conba has released its 2026 interim report. Total operating revenue was 3.701 billion yuan, up 10.21% year on year, and net profit attributable to the parent company was 378 million yuan, up 6.83% year on year. Net cash inflow from operating activities was 541 million yuan, up 35.10% year on year, marking a second consecutive year of growth. The company's debt-to-asset ratio was 29.37%, gross margin was 56.80%, return on equity was 5.35%, and diluted earnings per share was 0.15 yuan. The number of shareholders was 90,800, and the top ten shareholders held 38.72% of total share capital.

Conba announced that its wholly-owned subsidiary Inner Mongolia Conba has received a Drug Clinical Trial Approval Notice for Shexiang Tongxin Dropping Pills from the National Medical Products Administration, granting permission to conduct a clinical trial for heart failure with preserved ejection fraction, classified as Qi deficiency and blood stasis syndrome. The drug is registered as a Category 2.3 traditional Chinese medicine, representing an expansion of therapeutic indications. Shexiang Tongxin Dropping Pills are an exclusive traditional Chinese medicine variety of the company in China and a national second-class protected traditional Chinese medicine variety. They were approved for marketing in 2008, with the previously approved indication being stable exertional angina pectoris in coronary heart disease.

Conba's wholly owned subsidiaries Hangzhou Conba and Hong Kong Conba have signed an agreement with Adneuris Therapeutics to acquire exclusive development and commercialization rights to cebranopadol in Greater China. Cebranopadol is a first-in-class oral analgesic targeting both NOP and MOP receptors, has completed Phase III clinical trials, and is expected to submit a new drug application to the US FDA this year. Conba will pay an upfront fee of $17.5 million, up to $94 million in milestone payments, and tiered royalties.